RESHAPE LIFESCIENCES INC (RSLS)
US76090R2004 - Common Stock
We assign a fundamental rating of 3 out of 10 to RSLS. RSLS was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While RSLS seems to be doing ok healthwise, there are quite some concerns on its profitability. RSLS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RSLS had negative earnings in the past year.
RSLS had a negative operating cash flow in the past year.
RSLS had negative earnings in each of the past 5 years.
RSLS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of RSLS (-141.03%) is worse than 87.70% of its industry peers.
Looking at the Return On Equity, with a value of -297.07%, RSLS is doing worse than 83.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -141.03% | ||
| ROE | -297.07% | ||
| ROIC | N/A |
ROA(3y)-213.94%
ROA(5y)-174.81%
ROE(3y)-525.31%
ROE(5y)-397.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of RSLS (67.46%) is better than 74.87% of its industry peers.
RSLS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for RSLS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5Y9.59%
2. Health
2.1 Basic Checks
RSLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RSLS has less shares outstanding
RSLS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RSLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -142.46, we must say that RSLS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RSLS (-142.46) is worse than 95.72% of its industry peers.
RSLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -142.46 |
ROIC/WACCN/A
WACC9.01%
2.3 Liquidity
RSLS has a Current Ratio of 1.90. This is a normal value and indicates that RSLS is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.90, RSLS is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
RSLS has a Quick Ratio of 1.90. This is a bad value and indicates that RSLS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.89, RSLS is doing worse than 87.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.9 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 95.65% over the past year.
RSLS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -22.96%.
The Revenue has been decreasing by -0.95% on average over the past years.
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-239.64%
Revenue 1Y (TTM)-22.96%
Revenue growth 3Y76.07%
Revenue growth 5Y-0.95%
Sales Q2Q%-12.82%
3.2 Future
The Earnings Per Share is expected to grow by 41.36% on average over the next years. This is a very strong growth
Based on estimates for the next years, RSLS will show a quite strong growth in Revenue. The Revenue will grow by 16.06% on average per year.
EPS Next Y99.78%
EPS Next 2Y41.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.24%
Revenue Next 2Y16.06%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RSLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RSLS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RSLS's earnings are expected to grow with 41.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.36%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for RSLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RESHAPE LIFESCIENCES INC
NASDAQ:RSLS (11/4/2024, 8:00:02 PM)
6.05
+0.17 (+2.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.09M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -141.03% | ||
| ROE | -297.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.46% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.9 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y99.78%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-22.96%
Revenue growth 3Y76.07%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y